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ABSTRACT At stake in the May 2013 publication of the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), are billions
of dollars in insurance payments and government resources, as well as
the diagnoses and treatment of millions of patients. We argue that the
most recent revision process has missed social determinants of mental
health disorders and their diagnosis: environmental factors triggering
biological responses that manifest themselves in behavior; differing
cultural perceptions about what is normal and what is abnormal
behavior; and institutional pressures related to such matters as insurance
reimbursements, disability benefits, and pharmaceutical marketing. In
addition, the experts charged with revising the DSM lack a systematic
way to take population-level variations in diagnoses into account. To
address these problems, we propose the creation of an independent
research review body that would monitor variations in diagnostic
patterns, inform future DSM revisions, identify needed changes in mental
health policy and practice, and recommend new avenues of research.
Drawing on the best available knowledge, the review body would make
possible more precise and equitable psychiatric diagnoses and
interventions.
T
he American Psychiatric Associ-
ation is releasing the Diagnostic
and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5),
in May 2013. The manual is the as-
sociation’s comprehensive guide to the classifi-
cation of mental disorders, and the work’s cri-
teria are the most commonly used in US mental
health care as well as in international mental
health research.1
The identification and diagnosis ofmental dis-
orders are controversial and weighty topics.
Mental disorders are complex, and knowledge
about their causes and contributing factors is
still evolving. Historically, the diagnosis of men-
tal health disorders has been based more on pa-
tients’ symptom reports and behavior than on
specific,measurable biomarkers. TheDSMplays
an integral role in mental health treatment be-
cause revisions to the guide can in effect usher
diseases in andout of existencewith the strokeof
a pen, a factor that can have a profound effect on
individuals and institutions.
For an individual, a new diagnosis of a mental
disorder can carry a stigma that may affect per-
sonal relationships, career opportunities, and
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self-perception. Revisions to themanual can also
open and close individuals’ opportunities for
treatment, since insurance coverage and govern-
ment resources are typically allocated on the ba-
sis of DSM diagnoses.
Although the DSM-5 Task Force draws on out-
standing clinical expertise in defining disorders,
we believe that there is a need to inform future
updates of the DSM with science that embraces
the role of social and economic determinants
and influences in illness and its diagnosis. As
we discuss below, these determinants and
influences are critically important, yet they have
not received sufficient attention in the process of
producing updates to the DSM. We therefore
propose the formation of a research review body
that would systematically examine studies of so-
cial determinants of both mental illness and
mental illness diagnoses to assess their implica-
tions for DSM revisions, mental health policy,
and future research.
Background: Creation Of The DSM-5
The DSM-5 Task Force was convened by the
American Psychiatric Association. Its working
groups of recognized national and international
experts reviewed diagnostic criteria for mental
disorders, reviewed relevant research findings,
recommended changes to the criteria for diag-
noses and to the names of diagnoses, and rec-
ommended the creation of new diagnoses or the
elimination of existing ones.
For example, the DSM-5 Task Force recently
considered proposed revisions to the criteria for
subtypes of autism, depression, and psychosis.
The changes were predicted to disqualify half of
those who currently receive benefits for autism
spectrum disorders; to newly diagnose millions
of people with mood disorders; and to lead to
new prescriptions for antipsychotic medication
for the 70–80 percent of people who report hav-
ing odd thoughts or hallucinations to their doc-
tors but who heretofore have not qualified for a
psychotic disorder diagnosis.2 After vocal public
andprofessional resistance to these changes, the
DSM-5 Task Force largely backed down from
these proposed diagnostic changes.3
For institutions such as public and private hos-
pitals and clinics, as well as for individual health
professionals and pharmaceutical manufac-
turers, reimbursements for services and prod-
ucts depend on insurance coverage. A change
in the DSM that causes insurers to drop or add
coverage for a condition can cause providers and
others to alter thediagnoses they recordand, as a
result, the treatments they offer. Thus, the re-
lease of theneweditionof theDSM,whichprom-
ises to incorporate a host of scientific advances
to reflect new understandings of mental disor-
ders, is a highly anticipated event that will have
wide-ranging implications.
The DSM-5 revisions are taking place at a time
when there is increasing public scrutiny of the
accuracy and integrity of psychiatric diagnoses
andgrowingawarenessof the role that social and
economic influences can play, both in the inci-
dence of disease and in its diagnosis. These fac-
tors go beyond the reach of biological science
and psychiatry and are not adequately accounted
for in the understanding of disease currently
promoted by the DSM and its revision process.
Examples of how social environments can in-
fluence the rates ofmental disorders abound. For
example, exposure to the stress of living in a time
ofwarhas affects not only rates of post-traumatic
stress disorder4 but also rates of schizophrenia
among children who were in the womb when
their mothers were exposed.5,6
An example of how diagnoses are also subject
to nonmedical factors can be seen in the phar-
maceutical industry’s promotion of diagnoses—
such as attention deficit hyperactivity disorder7
and restless leg syndrome8—and medications to
treat them, as discussed below. Concerns about
the influence of the pharmaceutical industry has
led theAmerican Psychiatric Association and the
National Institute of Mental Health to call for
reduced corporate sponsorshipof psychiatric ed-
ucation and research.9,10
Categorizing Mental Disorders
Over the years the DSM has used different bases
to determinewhat constitutes amental disorder.
In 1952 the first edition categorized patients ac-
cording to psychoanalytic theories. In 1980 the
third edition shifted to diagnoses based on the
number and severity of symptoms, such as
changes in mood, appetite, and sleep. And in
2000 many of the experts convened to create
the fifth edition aspired to align diagnostic cri-
teria with changes in the central nervous system
that underlie mental disorders.
The DSM-5 Task Force was preoccupied with
establishing a neuroscientific basis for diagno-
sis,meaning that the group’smembers sought to
identify specific, measurable neurological phe-
nomena that couldbe linked to thebehaviors and
conditions that constitute mental disorders. In
practice, however, the DSM’s diagnoses con-
tinue to be organized around symptom clusters,
because evidence about the biological mecha-
nisms involved remains insufficient.11,12
Given the importance of social influences on
diagnostic patterns, however, mental health
leaders—including those revising the DSM—
should go a step further and understand how
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social and institutional processes shape both
the epidemiological distribution of disorders
in the population and the way that disorders
are identified and labeled. This understanding
is important because it is often difficult to dis-
tinguish between changes in the incidence of
disorders and changes in their identification.
It is also important because diagnoses spawn
debates about which signs, symptoms, and
behaviors are pathological and which are nor-
mal. The outcome of such debates affects how
ordinary people think about their problems and
also affects treatment, insurance coverage, insti-
tutions, and populations.
For example, children are three to four times
more likely to be diagnosedwith attentiondeficit
hyperactivity disorder by a US provider using
DSM-4 than by a European provider using the
International Classification of Diseases, Tenth
Revision.13 Consequently, 4 percent of children
in theUnitedStates areprescribed stimulants for
the condition, while only 0.3 percent of children
in the United Kingdom are.14 The US Centers for
Disease Control and Prevention recently re-
ported an increase of 41 percent in diagnoses
of attention deficit hyperactivity disorder in
the United States between 2002 and 2012 and
noted that 11 percent of all school-age children
have been diagnosed with the disorder.15
In addition, pharmaceutical manufacturers
often promote diagnoses to create a largemarket
for their products. For example, depression
awareness campaigns can foreshadow the mar-
keting of antidepressants.16 And manufacturers’
distribution of attention deficit symptom check-
lists to teachers and parents of children in
elementary schools was followed by 250–
900 percent increases in stimulant prescription
rates between 1990 and 1995.7
The ethnicity and socioeconomic status of pa-
tients also affect the application of DSM diag-
nostic criteria.17 Well-known examples include
the overdiagnosis—in comparison to other
groups—of psychotic disorders in black patients
and ofmood disorders inHispanic patients. This
overdiagnosis is thought to stem frommany fac-
tors. For example, populations may have differ-
ent rates of the disorders. However, some of the
factors involved in their overdiagnosis, such as
providers’ ethnic stereotypes and the varying
ways patients from different cultures present
their symptoms, can lead to inappropriate diag-
noses and inequalities in access to and appropri-
ateness of care.18,19
Social And Institutional Influences
On Diagnoses
Psychiatric conditions result from a combina-
tion of biological and environmental factors.
For instance, higher rates of depression in
women than in men have been linked to
differences between the sexes in physiological
responses to stress, in reproductive hormones,20
and in exposure to violence,21 as well as to the
targeting of women in mental health outreach
and antidepressant advertising campaigns.22
Women may also be more likely to be diagnosed
because they are more likely than men to see a
doctor, whether or not they are depressed.23,24
Given ethnic, sex, and class differences in di-
agnosis and treatment,7 as well as the increasing
number of prescriptions for psychotropic medi-
cations nationally and globally,25 researchers
should intensify their focus on the institutional,
social, and cultural determinants of diagnoses.
Doing so would enable mental health providers
to understand the full range of causes of mental
disorders and reduce bias in diagnoses.
Research along these lines can clarify whether
differences in disease diagnosis across groups
result from the diagnostic criteria, the way the
criteria are applied, or environmental factors
that influence people’s susceptibility to disor-
ders. These factors have different implications
for DSM revisions, as well as mental health pol-
icy and practice. Below we describe four types of
environmental influence on mental disorders
and their diagnosis.
Environmental Exposure Some disorders
are strongly associated with exposure to certain
social environments. One example is post-trau-
matic stress disorder among those exposed to
warfare.However, not all combatants are equally
likely to develop the disorder. It is more likely to
occur among people who have experienced
trauma in thepast, aremembers of ethnicminor-
ity groups, are immigrants, or have preexisting
psychiatric symptoms.26,27 The disorder is less
likely to occur among people with greater access
to economic and social resources.28
People who are already vulnerable to mental
disorders because of poverty or some other dis-
advantage are at an even more elevated risk of
developing a mental disorder when exposed to
psychological stressors. These interrelated fac-
tors are described by social theorists as the
“causes of causes”29 and “risks of risks,”30 mean-
ing that the fundamental causes are social in-
equalities that in turn cause disease, and that
risks of one kind lead to risks of other kinds.
The fundamental causes have implications for
diagnosis and intervention, whichmight inform
changes to institutions and policies to influence
other changes at the population level, as well as
how individuals are treated at the clinical level.
Social Context The level of awareness of a
disorder in a given communitymay influence the
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likelihood that the disorder will be diagnosed.
For example, one of the strongest predictors of a
diagnosis of autism is a child’s residential prox-
imity to another child with the diagnosis, with
clustering of diagnoses frequently occurring
in higher-income regions.31 This suggests that
learning about autism from a neighbor may in-
crease rates of diagnosis and that autismmay be
underdiagnosed in low-income populations.
In these and similar cases, population-level
interventions to improve the accuracy and equit-
able application of diagnoses would take into
account the diagnoses’ social context and would
therefore address the problem of systemic mis-
application of diagnostic criteria. In the case of
autism, interventionsmight include educational
programs for practitioners, school staff, and pa-
rents that explain the diagnostic criteria and
treatment options for autism.
Clinicians should be aware that parents who
are knowledgeable about autism and who are
seeking publicly funded treatment and other
benefits for their children might describe the
children’s symptoms in terms that fit autism’s
diagnostic criteria. For autism and other disor-
ders, the criteria themselves may make the diag-
nosis susceptible to bias by socioeconomic status
and social circumstances. Identifying and under-
standing the causes of diagnostic disparities can
lead to improved diagnostic criteria and their
more accurate application.
Institutional And Policy Factors Econo-
mic or policy constraints can influence psychi-
atric diagnoses. For example, insurance reim-
bursement rates that differ by diagnosis can lead
providers to assigndisease codes that allow them
to bill for more lucrative diagnoses and treat-
ments—a process known as “diagnosis creep.”
In addition, patients may require severe psy-
chotic diagnoses to be eligible for disability ben-
efits. Such factors may partially explain why the
rate of growth in the number of children and
young adults receiving Social Security benefits
for psychiatric disabilities has increased dra-
matically since the 1996 Personal Respon-
sibility and Work Opportunity Act reformed
the welfare system.32,33
The trend has led Marcia Angell, the former
editor of the New England Journal of Medicine, to
suggest thatmany low-income families are “find-
ing that applying for Supplemental Security
Income (SSI) payments on the basis of mental
disability is the only way to survive.” She quotes
David Autor, an economics professor at the
Massachusetts Institute of Technology, as saying
that these payments have “become the new
welfare.”34
The forces that influence diagnoses can have
major consequences for payers and patients.
Physicians are increasingly treating a range of
problematic behaviors, including attentional
and compulsive disorders in addition to psycho-
ses, with second-generation antipsychotics that
have side effects that include diabetes, high cho-
lesterol, and significant weight gain.35 Studies
have found that children insured by Medicaid
were 4 timesmore likely to receive antipsychotic
medications than children with private insur-
ance36 and that children receiving Social Secu-
rity disability benefits were 2.6 timesmore likely
than other children to receive antipsychotics,
mostly for attention deficit hyperactivity dis-
order and disruptive behavior disorder.37
The disproportionate use of high-risk medica-
tions by low-income children calls for an inves-
tigation of the interplay between diagnostic in-
centives and public policy.
Publicity And Marketing The pharmaceut-
ical industry is one of the most profitable in the
United States, with $300 billion in sales in 2009.
Furthermore, US consumers account for almost
half of theglobal spendingonpharmaceuticals.38
In 2010 one in five Americans was taking at least
one prescribed psychiatricmedication, and sales
of antipsychotics, antidepressants, and stimu-
lants used to treat attention deficit hyperactivity
disorder totaled $35 billion.39
Large investments are made in the promotion
of pharmaceuticals, with one study estimating
that 24.4 percent of pharmaceutical revenues
are spent on promotion.40 A popular marketing
strategy is topublicizeDSMdiagnosesbefore the
arrival in the marketplace of new medications
approved to treat them. For instance, the DSM-
5Task Force proposed including restless leg syn-
drome in its sleep disorders section.41 This pro-
posed change to the DSMwas not widely known
among physicians until the manufacturers of
Requip used the diagnosis in marketing, before
the Food and Drug Administration approved the
drug as a treatment for the condition.42Direct-to-
consumer advertising, another successful mar-
keting strategy,43 alerts thepublic tobehaviorsor
emotional states thatmay be symptoms of a diag-
nosable disorder.44
In the 1990s national working groups on psy-
chiatry and culture launched initiatives to ac-
count for cultural variation in the presentation
and definition of mental illness.45,46 These work-
ing groups, convened by the American Psy-
chiatric Association and the National Institute
of Mental Health, led to the DSM-4 Text
Revision’s “Outline for a Cultural Formula-
tion.”47 This outline teaches mental health pro-
viders how to take patients’ cultural beliefs and
practices into account during interviews, so that
the resulting diagnoses will be more accurate.
The outline’s section on culture-bound syn-
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dromes also characterizes symptom clusters
that are common in specific cultural groups,
such as ataque de nervios (“attack of nerves,” in
English)—a group of symptoms including panic,
fear, uncontrollable crying, shouting or aggres-
sion, dissociation, and sensations of heat—
among Caribbean and Latin American people.
A Psychiatric Diagnosis Review Body
The review body we propose would expand the
scope of such initiatives to include the influence
of social groups, institutions, and policies on
diagnostic patterns. Specifically, we recommend
the formation of an interdisciplinary group of
researchers that wouldmonitor population-level
data on variations in psychiatric diagnosis and
coordinate research on the institutional, social,
and cultural causes of those variations. Although
the DSM-5 Task Force draws on outstanding
clinical expertise in defining disorders, we have
shown in this article that there is aneed tounder-
stand the societal impact and underpinnings of
the manual, and a different type of expertise is
needed for this task.
The proposed review body would consist of
multidisciplinary scholars from such fields as
population health and the social sciences. Also,
theDSM is a substantial source of income for the
AmericanPsychiatric Association, generating an
estimated $5–$10 million in sales per year.48 It
thus would be important for the review body to
be governed by, and to have its members ap-
pointed by, processes independent of the asso-
ciation.Thiswould insulate the reviewbody from
pressure to consider the sales potential of the
DSM in various mental health provider markets
when making future revisions.
If possible, the review bodywould be hosted by
an existing respected scholarly organization
such as the Campbell Collaborative or the
National Academy of Sciences, both discussed
below. Having such an organization host the re-
view body would allow it to benefit from the
experience of the organization’s staff and its es-
tablished system of literature review. In addi-
tion, the host organization would solicit nomi-
nations and appoint a committee to select new
members for the review body as needed.
Building on the precedent of collaborative
funding set by the Ethical, Legal, and Social
Implications Program of the Human Genome
Project, also discussed below, the review body
would receive support from private and public
funders of health research, such as the Centers
forDisease Control and Prevention, theNational
Institutes ofHealth, andprivate foundations. If a
system of financing could be devised that would
keep the reviewbody independent of futureDSM
Task Forces, the review body could receive a
portion of the proceeds from the sale of the
DSM. The review body would provide a crucial
service by giving future DSM Task Forces a way
to account for the social determinants of diag-
nosis while sharing the costs and benefits of the
expertise needed for this mission.
Other funders would need to coordinate their
efforts to support the review body with the host
organization. Such partnerships have been suc-
cessful in the past. For example, the National
Institutes of Health’s Public-Private Partner-
ship Program spawned the Grand Challenges
in Global Health, an ongoing initiative49 that
was cosponsored by the Bill & Melinda Gates
Foundation and the Wellcome Trust.
The review body would publicly ask future
DSMTask Forces to respond to its findingswhen
they were relevant to diagnostic criteria develop-
ment. The review body would have four practical
duties, described in the following sections.
Develop A Research Agenda In Response To
Diagnostic Trends The review body would re-
view any emerging diagnostic pattern, such as
differences in rates of diagnosis by sex, ethnicity,
income, or geographic residence, or any un-
expectedly rapid increase in the rate of a specific
condition’s diagnosis. It would then recommend
follow-up research to appropriate funders.
These organizations could use the recommen-
dations in developing requests for proposals for
research studies. In an era in which funders may
lack the resources to perform impact assess-
ments of their planned funding initiatives, the
review body’s data-driven guidancewould offer a
way to improve the impact of mental health re-
search funders.
The review body would also act as a liaison
between governmental and nongovernmen-
tal research agencies to develop research prior-
ities basedon its reviews. Thiswould require that
the review body’smembers havemethodological
and theoretical expertise in population health
and social determinants of health.
Recommend DSM Revisions The review body
would also review research findings that resulted
from its collaborationwith theNational Institute
of Mental Health and other entities.When diag-
nostic criteria were determined to lead to under-
or overdiagnosis of a disorder, the review body
would recommend refinements in diagnostic cri-
teria for the disorder to future DSMTask Forces.
Ideally the American Psychiatric Association
would agree in advance of the creation of the
review body to have members of future DSM
Task Forces meet periodically with the review
body to consider its findings and recommenda-
tions. If such anagreementwerenot reached, the
review body would, as noted above, publicly ask
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future DSM Task Forces to respond to its find-
ings. For the review body to be effective and
credible, therefore, its members would need to
have recognized expertise in the application of
research to population health and an under-
standing of how social determinants of health
relate to clinical practice.
Recommend Reviews Of Health Care Policy
And Practice Although advocating for specific
policy changes would be beyond the purview of
the review body, it would communicate with pol-
icy-making bodies such as state and federal ex-
ecutive branches and legislatures, as well as
nongovernmental health policy institutes, to
highlight areas of policy that should be ad-
dressed to ensure equitable and accurate diag-
noses across populations.
For example, the review body could examine
the changes in patterns of diagnosis following
changes in clinical practice guidelines or insur-
ance policy, such as mandated coverage or men-
tal health parity laws. This function would re-
quire that review body members have expertise
in mental health policy analysis.
Mediate Scientific Controversies And
Diagnostic Diversity The review body would
be in a position to arbitrate controversies in the
literature regarding diagnostic patterns and
their causes. By attending to the impact of social
environments on biology in ways that can cause
local variations in the incidence of mental dis-
orders, the review body would help develop di-
agnostic criteria that would be useful interna-
tionally and cross-culturally.
This functionwould require expertise in cross-
cultural mental health research and biosocial
research, such as epigenetics and neuroplastic-
ity, which involve—among other things—how
environmental factors can influence gene ex-
pression and neural pathways in the brain.
The function would also require expertise in
global mental health policy and practice.
Precedents For A Psychiatric
Diagnosis Review Body
Other external review bodies have succeeded
in incorporating social science and policy
research as they monitor trends, mediate con-
troversies, and inform interventions. An exam-
ple is the Ethical, Legal, and Social Implications
Program, established as part of the Human
Genome Project in 1990.50 The Department of
Energy and the National Institutes of Health de-
vote 3–5 percent of their human genome re-
search budgets to this body, which designs and
reviews research on the societal impact of the
genome project, including issues of stigma, pri-
vacy, commercialization, clinical implementa-
tion, and fairness in the use of genetic informa-
tion. The program has led to numerous research
projects, federal reports, task forces, and educa-
tional initiatives.
Other research review organizations that
might serve asmodels for a psychiatric diagnosis
review body include the Campbell Collaboration,
an international research network that informs
public policy by issuing reviews of social science
evidence in education, criminal justice, and so-
cial welfare.51 The collaboration was formed as a
result of a 1999 internationalmeetingof scholars
in these fields, many of whom were active in
health care research reviews for the Cochrane
Collaboration.
Another example is the National Academy of
Sciences’ Division of Behavioral and Social
Sciences and Education, which identifies areas
of needed research in the behavioral sciences,
social sciences, education, and national statis-
tics for use in public policies and programs.52
The National Academy of Sciences is a nonprofit
organization formed by an act of Congress in
1863. It has had a social and behavioral sciences
branch since 1899.
Outcomes And Benefits
To its credit, the American Psychiatric Asso-
ciation now envisions developing an accurate
diagnostic system as an ongoing process, with
periodic updates, instead of the historical model
of long periods of time—sometimes a decade or
more—between formal revisions of the DSM.
More frequent updates to the manual would ac-
commodate new scientific evidence. The intent
of a more timely DSM is to help align the knowl-
edge emerging from psychiatric research with
mental health practice, thereby bringing treat-
ments to people who need them.
As the DSM-5 Task Force embarks on this new
model of continual, empirically based revision of
the manual, our proposed independent review
body couldproduce anumberof benefits. First, it
would enable future DSM Task Forces to correct
disparities stemming from differences in the ap-
plication of diagnostic criteria to various groups
distinguished by characteristics such as ethnic-
ity, race, socioeconomic status, cultural practic-
es, and sex or sexual orientation. Such correc-
tions would improve the scientific validity of the
DSM and increase public confidence in both the
manual and psychiatry as a medical profession.
Second, the review body would also bring
greater sophistication to explanations of mental
disorders by identifying social and institutional
causes that could be targeted for intervention.
Third and finally, the work of the review body
would heighten mental health practitioners’
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awareness of population-level differences in di-
agnoses, in some instances improving their abil-
ity to tailor diagnoses to patients’ demographic
characteristics and cultural backgrounds, and in
others making diagnoses more globally appli-
cable across diverse regions of the world.
Conclusion
Inadequate interdisciplinary review and collabo-
ration translate into missed opportunities to in-
crease the accuracy of explanations for mental
disorders. They also lead to suboptimal care and
outcome disparities for millions of patients at a
time when dramatic differences in psychiatric
diagnosis and treatment rates by socioeconomic
status, ethnicity, and geography have under-
mined public confidence in psychiatry.
As the DSM evolves, we must ensure the accu-
racy of psychiatric diagnoses and their equitable
use in health care by systematically reviewing
and applying the lessons in the population
health and social science literature. Our pro-
posed independent psychiatric diagnosis review
body has the potential to improve the DSM and
its revision process, as well as contributing to
better diagnosis and treatment of mental disor-
ders. ▪
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